Sanofi SA (ADR) (SNY) EPS Estimated At $0.79; Midsouth Bancorp Has 1.36 Sentiment

July 17, 2017 - By Winifred Garcia

MidSouth Bancorp, Inc. is a financial holding company. The company has market cap of $199.66 million. The Firm operates primarily through its wholly owned bank subsidiary, MidSouth Bank, N.A. It has a 21.16 P/E ratio. The Firm is operating principally in the community banking business by providing banking services to commercial and retail clients through the Bank.

Analysts expect Sanofi SA (ADR) (NYSE:SNY) to report $0.79 EPS on July, 31 before the open.They anticipate $0.05 EPS change or 6.76% from last quarter’s $0.74 EPS. SNY’s profit would be $1.97 billion giving it 15.21 P/E if the $0.79 EPS is correct. After having $0.76 EPS previously, Sanofi SA (ADR)’s analysts see 3.95% EPS growth. About 889,991 shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since July 17, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.

Among 10 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Sanofi-aventis Sa had 16 analyst reports since October 15, 2015 according to SRatingsIntel. Argus Research initiated Sanofi SA (ADR) (NYSE:SNY) on Thursday, April 6 with “Buy” rating. The rating was downgraded by Berenberg to “Hold” on Thursday, May 11. Barclays Capital upgraded the stock to “Overweight” rating in Thursday, May 12 report. On Monday, November 9 the stock rating was downgraded by Bernstein to “Mkt Perform”. The stock of Sanofi SA (ADR) (NYSE:SNY) has “Neutral” rating given on Wednesday, April 12 by JP Morgan. The company was downgraded on Thursday, December 10 by BNP Paribas. The firm has “Hold” rating given on Tuesday, May 3 by HSBC. HSBC downgraded the shares of SNY in report on Friday, April 7 to “Reduce” rating. The stock has “Sell” rating by JP Morgan on Friday, March 31. The firm has “Neutral” rating by JP Morgan given on Friday, April 21.

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company has market cap of $120.04 billion. The Company’s divisions are Pharmaceuticals, Human Vaccines , and Other. It has a 23.06 P/E ratio. The Pharmaceuticals segment comprises the commercial activities of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

About 18,949 shares traded. MidSouth Bancorp, Inc. (MSL) has risen 37.43% since July 17, 2016 and is uptrending. It has outperformed by 20.73% the S&P500.

Since January 1, 0001, it had 12 buys, and 13 selling transactions for $397,841 activity.

Analysts await MidSouth Bancorp, Inc. (NYSE:MSL) to report earnings on July, 25 after the close. They expect $-0.44 EPS, down 393.33% or $0.59 from last year’s $0.15 per share. After $0.15 actual EPS reported by MidSouth Bancorp, Inc. for the previous quarter, Wall Street now forecasts -393.33% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: